» Articles » PMID: 25036183

Palbociclib, a Selective Inhibitor of Cyclin-dependent Kinase4/6, Blocks HIV-1 Reverse Transcription Through the Control of Sterile α Motif and HD Domain-containing Protein-1 (SAMHD1) Activity

Overview
Journal AIDS
Date 2014 Jul 19
PMID 25036183
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sterile α motif and HD domain-containing protein-1 (SAMHD1) inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides. SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation. However, the exact mechanism of SAMHD1 regulation in primary cells is unclear. We explore the effect of palbociclib, a CDK6 inhibitor, in HIV-1 replication.

Methods: Human primary monocytes were differentiated into macrophages with monocyte-colony stimulating factor and CD4 T lymphocytes stimulated with phytohaemagglutinin (PHA)/interleukin-2. Cells were treated with palbociclib and then infected with a Green fluorescent protein-expressing HIV-1 or R5 HIV-1 BaL. Viral DNA was measured by quantitative PCR and infection assessed by flow cytometry. Deoxynucleotide triphosphate (dNTP) content was determined using a polymerase-based method.

Results: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation. HIV-1 replication was blocked by AT7519 (66.4 ± 3.8%; n = 4), roscovitine (47.3 ± 3.9%; n = 4) and purvalanol A (55.7 ± 15.7%; n = 4) at subtoxic concentrations. Palbociclib, a potent and selective CDK6 inhibitor, blocked SAMHD1 phosphorylation, intracellular dNTP levels, HIV-1 reverse transcription and HIV-1 replication in primary macrophages and CD4 T lymphocytes. Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160. The antiviral effect was lost when SAMHD1 was degraded by Vpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect.

Conclusions: Our results indicate that SAMHD1-mediated HIV-1 restriction is controlled by CDK as previously suggested but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation. Our study provides a new signaling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.

Citing Articles

Unveiling the Connection: Viral Infections and Genes in dNTP Metabolism.

Lo S, Lai M, Yang C, Li H Viruses. 2024; 16(9).

PMID: 39339888 PMC: 11437409. DOI: 10.3390/v16091412.


Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review.

Liu M, Peng W, Ji X Mini Rev Med Chem. 2024; 25(3):178-189.

PMID: 39185650 DOI: 10.2174/0113895575311618240820103549.


Nucleoside Analog 2',3'-Isopropylidene-5-Iodouridine as Novel Efficient Inhibitor of HIV-1.

Glumakova K, Ivanov G, Vedernikova V, Shyrokova L, Lebedev T, Stomakhin A Pharmaceutics. 2023; 15(10).

PMID: 37896149 PMC: 10610023. DOI: 10.3390/pharmaceutics15102389.


BMS-265246, a Cyclin-Dependent Kinase Inhibitor, Inhibits the Infection of Herpes Simplex Virus Type 1.

Jiang L, Yu Y, Li Z, Gao Y, Zhang H, Zhang M Viruses. 2023; 15(8).

PMID: 37631985 PMC: 10459710. DOI: 10.3390/v15081642.


Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.

Hajjo R, Sabbah D, Abusara O, Kharmah R, Bardaweel S Viruses. 2023; 15(2).

PMID: 36851782 PMC: 9966946. DOI: 10.3390/v15020568.